CGRP inhibitors
Overview
CGRP inhibitors are a class of therapies used primarily in migraine care. They target calcitonin gene-related peptide (CGRP) or its receptor, a signaling pathway strongly linked to migraine attacks. CGRP is a neuropeptide involved in pain transmission, dilation of blood vessels, and inflammatory signaling in the trigeminal nervous system. Because migraine is now understood as a complex neurologic disorder rather than simply a vascular headache, CGRP-directed therapies represent a major shift toward mechanism-based treatment.
This category includes monoclonal antibodies designed for migraine prevention and small-molecule CGRP receptor antagonists (often called gepants) used in acute treatment, preventive treatment, or both depending on the product. In conventional care, these therapies are often discussed for people with episodic or chronic migraine, especially when older preventive medications have been poorly tolerated, ineffective, or not suitable. Research suggests they can reduce monthly migraine days and improve quality of life for many patients, though response varies.
CGRP inhibitors are significant because they were among the first migraine therapies developed specifically for migraine biology rather than adapted from drugs originally created for other conditions such as epilepsy, depression, or hypertension. Their arrival has expanded options for patients and clinicians, particularly in cases where disability remains high despite standard approaches. At the same time, they are not a universal solution: cost, access barriers, long-term safety monitoring, and individual variability remain important considerations.
From a broader integrative health perspective, CGRP inhibitors are often viewed as one component of care rather than the whole picture. Migraine is influenced by genetics, sleep, hormones, stress, sensory triggers, autonomic function, and comorbid conditions. For that reason, both conventional and traditional systems often place this treatment within a wider framework that may include trigger management, lifestyle regulation, mind-body practices, and individualized supportive therapies. Decisions about their use are typically made in consultation with a qualified healthcare professional familiar with headache disorders.
Western Medicine Perspective
Western Medicine Perspective
In conventional medicine, CGRP inhibitors are understood through modern migraine pathophysiology. During migraine attacks, CGRP levels rise and contribute to activation of the trigeminovascular system, sensitization of pain pathways, and neurogenic inflammation. Blocking CGRP signaling may reduce the likelihood of attacks or help abort an attack in progress. This mechanism distinguishes CGRP inhibitors from older migraine medications that were not designed specifically around the biology of migraine.
Current western approaches divide these therapies into two broad groups. Monoclonal antibodies such as erenumab, fremanezumab, galcanezumab, and eptinezumab are used mainly for prevention. Gepants such as ubrogepant, rimegepant, and atogepant are used for acute treatment, prevention, or both depending on the agent and indication. Clinical trials and post-marketing data indicate these therapies can be effective for many patients with episodic and chronic migraine, and they are generally considered better tolerated than some traditional preventives. Reported adverse effects vary by drug but may include constipation, injection-site reactions, nausea, fatigue, and hypersensitivity reactions; longer-term safety continues to be monitored.
Conventional headache medicine also considers practical issues such as patient selection, coexisting cardiovascular risk, pregnancy considerations, medication overuse headache, insurance requirements, and comparative effectiveness against older options like beta blockers, antiepileptics, onabotulinumtoxinA, or antidepressants. Although CGRP-targeted therapies have a strong evidence base in migraine, they are not considered interchangeable for every patient. Their role is usually assessed within a personalized migraine management plan developed with a healthcare provider.
Eastern & Traditional Perspective
Eastern/Traditional Medicine Perspective
Traditional systems of medicine do not describe illness in terms of CGRP signaling, but many do have longstanding frameworks for recurrent headache syndromes. In Traditional Chinese Medicine (TCM), migraine-like patterns may be interpreted through concepts such as Liver yang rising, Liver fire, phlegm obstruction, blood stasis, or deficiency patterns involving qi, blood, yin, or kidney essence. A CGRP inhibitor would not traditionally be classified within these frameworks, yet from an integrative perspective it may be viewed as a modern symptomatic or preventive intervention that can coexist with pattern-based care.
In Ayurveda, recurrent headaches may be understood through imbalances involving Vata, Pitta, or mixed doshic patterns, with attention to digestion, stress, sleep, and sensory overload. Similarly, naturopathic and other traditional systems often emphasize terrain, triggers, inflammation, autonomic balance, and constitutional susceptibility. These traditions generally focus on individualized assessment rather than a single pathway target, so a CGRP inhibitor may be seen as addressing one biological mechanism while broader contributors remain relevant.
Evidence for combining CGRP inhibitors with traditional modalities is still limited, and research is more robust for some nonpharmacologic migraine approaches—such as acupuncture, relaxation training, biofeedback, and certain lifestyle-based interventions—than for fully integrated care models. A balanced integrative view recognizes that conventional biologic treatments and traditional whole-person frameworks need not be mutually exclusive, but coordination with qualified healthcare professionals is important, particularly because migraine can overlap with other neurologic or systemic conditions.
Related Topics
Migraine
Migraine — a condition in the health ontology.
How They Relate
Migraine & CGRP inhibitors
Migraine is a neurologic pain disorder marked by recurrent attacks often accompanied by nausea, light or sound sensitivity, and functional impairment. A key player in migraine biology is calcitonin...
Evidence & Sources
Supported by multiple clinical trials and systematic reviews
- New England Journal of Medicine
- JAMA
- The Lancet Neurology
- Headache: The Journal of Head and Face Pain
- Cephalalgia
- American Headache Society
- National Institute for Health and Care Excellence (NICE)
- National Institute of Neurological Disorders and Stroke (NINDS)
- National Center for Complementary and Integrative Health (NCCIH)
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication regimen.